#cma
Latest news and interesting information about cma.
Artemis III crew announced
NASA announces Artemis III crew: Andre Douglas, Frank Rubio, Randy Bresnik and Luca Parmitano to test Moon technologies.
NASA chief: No evidence of aliens
NASA Administrator Jared Isaacman says there is no evidence of aliens or UFOs, supporting transparency efforts.
NASA to send unmanned ships to Moon every month
NASA plans monthly unmanned Moon missions from 2027, preparing for a lunar base.
FITB: SWOT Analysis and Outlook
FITB stock SWOT analysis. Details on CMA acquisition, financial projections, and risks. Expert insights on Bond.az.
Comerica SWOT Analysis: Merger Ahead
Comerica SWOT analysis: regional bank at merger milestone, margin pressure, and stock valuation. Read on Bond.az.
Immix Biopharma Closes $140.65M Stock Offering
Immix Biopharma closes $140.65 million stock offering. Company advances AL Amyloidosis treatment with NXC-201.
CMA CGM to operate two Syrian dry ports under new deal
CMA CGM signed a deal to operate two dry ports in Syria's Adra and Aleppo free zones. Rail link between Latakia and Adra resumes after 14 years.
Immix Biopharma reports 95% complete response rate in trial
Immix Biopharma's NEXICART-2 trial achieves 95% complete response rate in AL Amyloidosis patients. Promising results for CAR-T therapy NXC-201.
Clyburn targeted: SC advances new map
South Carolina Republicans advance a new congressional map targeting Democrat Jim Clyburn, with primaries postponed.
Hormuz crisis reshapes global trade
Hormuz crisis: shipping giants shift routes as costs soar. Red Sea and Gulf of Oman ports become alternatives.
Final Report on Getty Images and Shutterstock Merger
The UK CMA has issued its final report on the Phase 2 review of the proposed Getty Images and Shutterstock merger.
Louisiana, South Carolina advance new congressional maps
Republicans in Louisiana and South Carolina advance new congressional maps, eliminating Democratic districts. The Supreme Court ruling enables redistricting.
Mira stock rises on Phase 1 trial results
Mira Pharmaceuticals shares rise 5% after positive Phase 1 results for Ketamir-2. Company advances toward Phase 2a for chemotherapy-induced neuropathy.
...